

**Information and Disclosure Statement  
Pursuant to Rule 15c2-(11) (a) (5)  
For**

**ReBuilder Medical Technologies, Inc.**

**Quarterly Disclosure Report prepared for the three (3) month period beginning January 1,  
2012 with the period ending March 31, 2012.**

**All information contained in this information and Disclosure Statement has been compiled  
to fulfill the disclosure requirements of Rule 15c2-11 (a) (5) promulgated under the  
Securities Exchange Act of 1934, as amended. The enumerated captions contained herein  
correspond to the sequential format as set forth in the rule.**

**COMPANY HIGHLIGHTS**

- **The Company Is Receiving Payments From Medicare**
- **The Company Is Receiving Payments From Insurance Companies**
- **The Company Is Receiving Payments From Individual Customers**

**Item I: The Exact Name Of The Issuer And The Address Of Its Principal Executive  
Offices**

ReBuilder Medical Technologies, Inc. (NV) (hereinafter referred to as "Issuer") incorporated in the State of Nevada.

**Predecessors:**

October 20, 1995	Nupac International, Inc. (Nupac)
March 1, 2003	Nupac changed its name to International Mart Corporation
November 2006	International Mart Corporation changed its name to Sycamore Development Group.
March 2007	Sycamore Development Group changed its name to ReBuilder Medical Technologies, Inc.
March 28, 2007	ReBuilder Medical Technologies, Inc. informally affiliated with ReBuilder Medical, Inc. of West Virginia, a medical product manufacturing operation since 1988 involved in sales, marketing, and product development.

The Address Of The Issuers Principal Executive Offices

636 Treeline Drive, Suite B  
Charles Town, WV 25414  
Tel: 877-585-8230  
Fax: 304-725-4915  
Web sites: [www.rebuilder-dme.com](http://www.rebuilder-dme.com)

General Inquiries: David B. Phillips, Ph.D.  
636 Treeline Drive, Suite B  
Charles Town, WV 25414

[davidphillipsmail@yahoo.com](mailto:davidphillipsmail@yahoo.com)

Media/Investor Relations:

None, managed in house.

**Item II: Shares Outstanding**

Only one class of stock and that is Common. The CUSIP Number is 75618R205 and the trading symbol is RBRM.

Period End Date Is 3/31/2012

Total Shares For Common Stock Class 183:	50,000,000
Total Outstanding Shares In 47 Certificates:	44,544,203
Total Restricted Shares In 22 Certificates:	42,377,005
Total Non Restricted Shares in 25 Certificates:	2,167,198
Total Active shareholders:	22

**Item III: Interim Financial Statements**

See attached Current Financial Statements. These statements have not been audited.

Balance Sheet: Ending March 31, 2012

Income Statement: January 1 – March 31, 2012

Statement of Cash Flows: January 1, 2012 – March 31, 2012

Statement of Stockholders' Equity: March 31, 2012

**REBUILDER MEDICAL TECHNOLOGIES, INC.  
Balance Sheet (Unaudited)  
For the Quarter Ended March 31, 2012**

	Mar 31, 12
<b>ASSETS</b>	
<b>Current Assets</b>	
Checking Accounts	10,094.95
Accounts Receivable	107,189.62
<b>Other Current Assets</b>	
Inventory Asset	4,444.96
Loan – Employee	245.60
Prepaid Insurance	0.00
Due from RMI	25,705.44
<b>Total Other Current Assets</b>	30,396.00
<b>Total Current Assets</b>	147,680.57
<b>TOTAL ASSETS</b>	<b>147,680.57</b>
<b>LIABILITIES &amp; EQUITY</b>	
Liabilities	

<b>Current Liabilities</b>	
<b>Accounts Payable</b>	
Accounts Payable	156,826.67
<b>Total Accounts Payable</b>	156,826.67
<b>Credit Cards</b>	
Credit Cards	9,226.47
<b>Total Credit Cards</b>	9,226.47
<b>Other Current Liabilities</b>	
Loan – Advance Me	24,982.69
Loan – Lumpp	1,500.00
Due to Whitehall	96,134.70
Due to D Phillips	127,500.00
Due to M Phillips-04	333,896.72
Due to M Phillips	38,076.90
Due to ReBuilder R&D LP	153,048.95
Payroll Liabilities	0.00
<b>Total Other Current Liabilities</b>	775,139.96
<b>Total Current Liabilities</b>	941,193.10
<b>Total Liabilities</b>	941,193.10
<b>Equity</b>	
Additional Paid In Capital	382,027.27
Capital Stock	390,000.00
Retained Earnings	-1,474,496.87
Net Loss	-91,042.93
<b>Total Equity</b>	-793,512.53
<b>TOTAL LIABILITIES &amp; EQUITY</b>	<b>147,680.57</b>

**REBUILDER MEDICAL TECHNOLOGIES, INC.**  
**Income Statement (Unaudited)**  
**For the Quarter Ended March 31, 2012**

	<b>Jan – Mar 12</b>
<b>Income</b>	
<b>Income</b>	
Medicare Payments	110,712.58
Patient Payments	9,557.69
Insurance Payments	63,015.85
<b>Total Income</b>	183,286.12
<b>Total Income</b>	183,286.12
<b>Cost of Goods Sold</b>	
*Cost of Goods Sold	
Product Cost	55,317.41

Shipping Cost	3,935.39
Total *Cost of Goods Sold	59,252.80
Total COGS	59,252.80
Gross Profit	124,033.32
Expense	
Public Company Expense	893.04
Operating Expense	
Accreditation Fee	523.00
Advertising Expense	0.00
Bad Debt Expense	0.00
Bank Service Charge	220.75
Consulting Expense	884.60
Employee Benefit	181.38
Insurance Expense	2,093.64
Interest Expense	52.04
IT Hard Cost Expense	626.95
Lease – Facility	4,500.00
Lease – Storage	12,000.00
Legal & Professional Fees	500.00
Office Expense	2,031.29
Payroll Expense	95,489.85
Payroll Tax Expense	28,132.00
Payroll Processing Fee	252.52
Professional Fees and License	41,177.24
Royalty	24,169.72
Surety Bond Renewal	555.00
Taxes	500.00
Telephone	293.23
Total Operating Expense	214,183.21
Total Expense	215,076.25
Net Loss	-91,042.93

**REBUILDER MEDICAL TECHNOLOGIES, INC.**  
**Statement of Changes in Stockholders' Equity**  
**For the Quarter Ended March 31, 2012**  
**(Unaudited)**

	<b>Common Stock</b>	<b>Additional Paid in Capital</b>	<b>Retained Earnings</b>	<b>Total</b>
Balance, January 1, 2012	390,000.00	382,027.27	-1,474,496.87	-702,469.60
Investment by Owner				0.00
Net Loss			-91,042.93	-91,042.93
Balance, March 31, 2012	390,000.00	382,027.27	-1,565,539.80	-793,512.53

**REBUILDER MEDICAL TECHNOLOGIES, INC.**  
**Statement of Cash Flows**  
**For the Quarter Ending March 31, 2012**  
**(Unaudited)**

<b>OPERATING ACTIVITIES</b>		
Net Loss		-91,042.93
Adjustments to reconcile Net Income to net cash provided (used) by operations		
Decrease in inventory		3,802.26
Decrease in accounts receivable		58,411.05
Decrease in prepaid insurance		1,441.14
Decrease in notes receivable		8,566.29
Decrease in accounts payable		-833.97
Decrease in credit card liability		-467.29
Increase in due to Whitehall		13,250.00
Increase in due to R&D		24,169.72
Decrease in due to Advance Me		-9,289.04
	Net cash provided by Operating activities	99,050.16
<b>INVESTING ACTIVITIES</b>		
Increase in fixed assets		0.00
	Net cash provided by Investing Activities	0.00
<b>FINANCING ACTIVITIES</b>		
Investment by owner		0.00
	Net cash provided by Financing Activities	0.00
Net cash increase for period		8,007.23
Cash at beginning of period		2,087.72
Cash at end of period		10,094.95

**Item IV: Management's Discussion And Analysis Or Plan Of Operation**

The company has billed Medicare for the entire calendar year ending December 31, 2011 thru the present. The company will continue to be focused upon its distribution efforts as a DME (Durable Medical Equipment) supplier, selling only to those customers who have Medicare or private insurance. This will simplify the accounting and allow the company to focus on its most profitable business opportunities.

The company has changed its focus from marketing to consumers to marketing to physicians.

Several Cancer Treatment Centers such as the Cancer Treatment Centers of America (CTCA), and the Rockefeller Cancer Treatment Center in Little Rock AK continue to use the ReBuilder as

their preferred treatment for those patients who have developed chemotherapy related peripheral neuropathy and business from that source is increasing. CTCA is developing a clinical protocol to test the ReBuilder with patients who are about to undergo chemotherapy before the symptoms of peripheral neuropathy develop.

So far over 4,000 thousand physicians have prescribed the ReBuilder on a 30 day trial basis and after re-evaluating the patient, recommended the purchase of the ReBuilder to Medicare or Insurance upon behalf of their patients. Initial analysis of this data indicates upwards of 90% of the patients have responded successfully to the ReBuilder for the doctor to confirm that success and Medicare has been fully satisfied and paid for the purchase of the ReBuilder.

The company assembling the data and present it in the form of a published study. This study can now be found on the company's website.

That study will indicate that over 4,000 doctors tested the ReBuilder on 4,000 patients who had exhausted all other forms of treatment that did not work, and these 4,000 physicians from all over the USA found the ReBuilder to be over 90% effective!

The company will continue to grow through the use of internal funding, outside borrowing when necessary, and through the sales of properly registered or properly exempted securities. .

There have been no defaults upon senior securities, nor do we have any senior securities. The Company has not defaulted on any of its obligations.

The new Medicare billing company's performance was poor, so they have been replaced.

Certain accounts receivable relative to Medicare payments were recalculated based on experience to reflect the actual performance of the Medicare System. Medicare has significantly changed its payment policy to delay payments as long as possible and to deny claims for frivolous reasons such as the illegibility of the physician's signature. This signature issue is to force physicians to use the electronic reporting system rather than using manual systems, and it uses the DME providers to force the issue. The result is that many claims were denied and the company was forced to engage a new program to appeal these claims. Thus the company only accounted this quarter for that portion of claims it feels are readily payable and to be received by the company.

Stock volatility is still an issue with wide fluctuations that the company feels do not reflect the underlying value of the company, both high and low prices and is seeking to stabilize the price with larger trading volumes and better public awareness of the company's value.

Recently the Company was contacted by some investors concerning financial transactions involving the Company shares. These shares were offered by brokers totally unrelated to RBRM. These transactions were purely private, between the buyer and seller. RBRM was neither the buyer nor the seller. The company is not involved whatsoever.

It appears that the issue has been resolved successfully and there is not litigation pending or

threatened.

The company is currently fielding offers to merge with companies with emerging products in an effort to create a better foundation for share values. If this occurs, the company will likely sell off the DME business and focus on a new endeavor.

**Item V: Legal Proceedings**

There are no current or pending legal proceedings involving the Company.

**Item VI: Defaults Upon Senior Securities**

There have been no defaults upon Senior Securities or indebtedness of the Company.

**Item VII: Other Information**

There is no other information to report for the Company.



**Item VIII: Exhibits**

There are no Exhibits

**Item IX: Certifications**

I, David B. Phillips, CEO of RBRM certify that:

1. I have reviewed this information and Disclosure Statement of RBRM.
2. Based on my knowledge, this disclosure does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Signature  Title CEO Date April 20, 2019  


I, Margaret A. Phillips, CFO of RBRM certify that:

4. I have reviewed this information and Disclosure Statement of RBRM.

